We are live on
!
Find out more
WP
Woodline Partners Portfolio holdings
AUM
$26.4B
1-Year Est. Return
44.85%
This Fund
S&P 500
This Quarter
Est. Return
+32.2%
1 Year Est. Return
+44.85%
3 Year Est. Return
+131.23%
5 Year Est. Return
+174.12%
10 Year Est. Return
–
AUM
$2.52B
AUM Growth
+$1.12B
(+80%)
Cap. Flow
+$772M
Cap. Flow
% of AUM
30.59%
Top 10 Holdings %
Top 10 Hldgs %
26.22%
Holding
205
New
69
Increased
52
Reduced
26
Closed
58
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Intel
INTC
|
+$62.5M |
| 2 |
Johnson & Johnson
JNJ
|
+$61M |
| 3 |
Fidelity National Information Services
FIS
|
+$54.2M |
| 4 |
KLA
KLAC
|
+$44.1M |
| 5 |
PayPal
PYPL
|
+$41.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$65.7M |
| 2 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$46.8M |
| 3 |
Alphabet (Google) Class A
GOOGL
|
+$46.5M |
| 4 |
IMMU
Immunomedics Inc
IMMU
|
+$41.2M |
| 5 |
Analog Devices
ADI
|
+$23.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 46.91% |
| 2 | Technology | 35.52% |
| 3 | Communication Services | 5.66% |
| 4 | Consumer Discretionary | 4.26% |
| 5 | Industrials | 2.57% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
AT&T
T
$159B
| $18M | 0.71% |
790,384
+387,426
| +96% | +$8.82M |
|
52
Cue Biopharma
CUE
$113M
| $16.2M | 0.64% |
+21,980
| New | +$15.9M |
|
53
Baidu
BIDU
$37.7B
| $15.8M | 0.63% |
131,638
-163,992
| -55% | -$17.5M |
|
54
Ironwood Pharmaceuticals
IRWD
$696M
| $15.6M | 0.62% |
+1,511,366
| New | +$15.5M |
|
55
Viavi Solutions
VIAV
$9.12B
| $15.3M | 0.61% |
+1,204,153
| New | +$14.4M |
|
56
Knowles
KN
$3.13B
| $14.9M | 0.59% |
974,328
+648,648
| +199% | +$9.67M |
|
57
Cadence Design Systems
CDNS
$93.6B
| $14.3M | 0.57% |
+149,136
| New | +$12.5M |
|
|
GWPH
58
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
| $13.8M | 0.55% |
112,785
-105,740
| -48% | -$12M |
|
59
TripAdvisor
TRIP
$1.65B
| $13.3M | 0.53% |
698,810
+358,005
| +105% | +$6.84M |
|
60
Diodes
DIOD
$3.78B
| $13M | 0.52% |
257,299
+132,981
| +107% | +$6.36M |
|
61
Teleflex
TFX
$6.05B
| $12.1M | 0.48% |
33,336
+556
| +2% | +$192K |
|
62
Flex
FLEX
$41.7B
| $12.1M | 0.48% |
+1,567,024
| New | +$11.3M |
|
|
63
Analog Devices
ADI
$179B
| $12.1M | 0.48% |
98,629
-211,135
| -68% | -$23.2M |
|
|
SAGE
64
DELISTED
Sage Therapeutics
SAGE
| $12M | 0.47% |
287,943
+129,116
| +81% | +$4.69M |
|
65
Gilead Sciences
GILD
$162B
| $11.8M | 0.47% |
+153,614
| New | +$11.8M |
|
66
Jazz Pharmaceuticals
JAZZ
$15.9B
| $11.5M | 0.45% |
+103,804
| New | +$11.5M |
|
67
AMN Healthcare
AMN
$1.3B
| $11.3M | 0.45% |
+248,937
| New | +$11.9M |
|
|
MYOK
68
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $11M | 0.44% |
114,039
+49,731
| +77% | +$4.15M |
|
|
DRNA
69
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $11M | 0.44% |
433,611
-198,489
| -31% | -$4.28M |
|
70
Shopify
SHOP
$152B
| $10.6M | 0.42% |
+111,990
| New | +$7.77M |
|
71
Pacira BioSciences
PCRX
$1.04B
| $10.5M | 0.42% |
200,720
+8,488
| +4% | +$355K |
|
72
Walt Disney
DIS
$167B
| $10M | 0.4% |
+89,719
| New | +$9.9M |
|
73
F5
FFIV
$22.9B
| $9.84M | 0.39% |
70,577
+60,702
| +615% | +$8.17M |
|
74
QuidelOrtho
QDEL
$1.14B
| $9.67M | 0.38% |
+43,230
| New | +$6.77M |
|
75
Monolithic Power Systems
MPWR
$70.1B
| $9.45M | 0.37% |
+39,878
| New | +$8.07M |
|
Similar funds
PAM
TCIIS
UIM
Woodline Partners's Q2 2020 Portfolio in Review
As of Q2 2020, Woodline Partners held 205 positions worth $2.52B, up 80% from $1.4B the previous quarter. Its ten largest holdings account for 26% of the portfolio.
Woodline Partners deployed $772M of net new capital in Q2 2020, opening 69 new positions and adding to 52 existing holdings. Its largest new stake was Johnson & Johnson: 418,880 shares worth $58.9M.
By sector, the portfolio is most concentrated in Healthcare at 47% of assets, up from 46% a quarter earlier, followed by Technology and Communication Services.
On the sell side, the largest reduction was Immunomedics Inc, an estimated $41.2M trimmed.
- Woodline Partners's largest Q2 2020 buy was Johnson & Johnson: 418,880 shares worth $58.9M.
- Woodline Partners added most to Intel in Q2 2020, an estimated $62.5M increase.
- Woodline Partners's biggest Q2 2020 reduction was Immunomedics Inc, cutting an estimated $41.2M.
- Woodline Partners fully exited Pfizer in Q2 2020, selling an estimated $65.7M.
- Woodline Partners's ten largest holdings make up 26% of its $2.52B portfolio in Q2 2020.
- Woodline Partners opened 69 new positions and closed 58 in Q2 2020.
- Woodline Partners's portfolio value rose 80% quarter-over-quarter to $2.52B.
Based on Woodline Partners's 13F filing for Q2 2020, filed 14 Aug 2020.